Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch
EAST SETAUKET, N.Y., Nov. 6, 2014 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), a clinical-stage public pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer, has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its lead compound, LB-100. For more information, see: http://www.iirusa.com/therapeuticareapartnership/presentingcos.xml
John S. Kovach, MD, President of Lixte, will present at Informa's Therapeutic Area Partnerships meeting taking place November 19-21 at the Hyatt Regency in Boston. Dr. Kovach's presentation on LB-100, a phosphatase inhibitor in Phase I development for use in combination with chemotherapy in solid tumors, will occur at 10:30 am on November 20 within Track 3 (Oncology).
Products selected as one of the Most Interesting Oncology Projects to Watch have met rigorous criteria including unmet medical need, market potential, diversity of indications, strong science, partnering opportunities, and potential for new opportunities beyond initial indications.
"Selected products have been screened using a strict set of judging criteria for the Top 10 award and represent what Kantar Health staff consider among the most attractive opportunities the industry has to offer," said Bill Bagwell, General Manager, Oncology, Kantar Health. "As an industry leader in oncology strategic research and consulting, it is exciting to give these companies exposure to potential investors, partners and acquirers."
"We welcome the opportunity to discuss the clinical development of our lead serine/threonine phosphatase inhibitor, LB-100, at Informa's Therapeutic Area Partnership meeting," said Dr. Kovach. "We are particularly pleased that Lixte Biotechnology has been selected by the Kantar Health staff as having one of the top ten most interesting oncology projects. Our clinical-stage compound, LB-100, is a novel small molecule that in animal models enhances the therapeutic effectiveness of cytotoxic anti-cancer drugs widely used against solid tumors. In addition, in pre-clinical studies, LB-100 has single agent activity against certain hematologic diseases. If these results are borne out in the clinic, LB-100 has the potential to be a valuable component of treatments for several, if not many, cancers."
About Lixte Biotechnology Holdings, Inc.
Lixte is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development which the company believes have broad therapeutic potential not only for cancer but for other debilitating and life-threatening diseases. Lixte's unique phosphatase inhibitor, LB-100, is in a Phase I cancer trial at two NCI designated Comprehensive Cancer Centers (see ClinicalTrials.gov: Identifier NCTO1837667).
About the Therapeutic Area Partnerships (TAP)
A meeting for the sharpest minds in biopharma. Since its launch eight years ago, TAP has come to be regarded as the industry's premier biopharmaceutical partnering event. A uniquely efficient gathering, TAP brings together decision-makers to assess the most promising drug programs available for partnering in: Oncology, Cardiovascular, Neuroscience, Infectious Diseases, Anti-Inflammatory/Autoimmune Diseases, Advanced Therapies (Cellular and Gene Therapies, Rare Diseases and other high value and niche areas).
Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry's most productive events.
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the Quarterly Report on Form 10Q for June 30, 2014.
For additional information, please see: www.lixte.com
SOURCE Lixte Biotechnology Holdings, Inc.
Released November 6, 2014